Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cyteir Therapeutics Inc | CYT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.02 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.02 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.67 - 3.19 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.02 | USD |
Cyteir Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 108.71M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cyteir Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 3.13 | 3.19 | 2.99 | 3.06 | 241,813 | -0.11 | -3.51% |
| 6 Months | 3.02 | 3.19 | 2.96 | 3.05 | 135,790 | 0.00 | 0.00% |
| 1 Year | 2.02 | 3.19 | 1.67 | 2.80 | 173,805 | 1.00 | 49.50% |
| 3 Years | 16.50 | 23.10 | 1.13 | 5.54 | 135,425 | -13.48 | -81.70% |
| 5 Years | 16.50 | 23.10 | 1.13 | 5.54 | 135,425 | -13.48 | -81.70% |
Cyteir Therapeutics Description
| Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing the next generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Its lead program is CYT-0851, which is designed to exploit a novel synthetic lethality between overexpression of a family of DNA damaging enzymes called cytidine deaminases and functional inhibition of homologous recombination, a DNA repair pathway critical for the survival of some cancers. Its Pre-clinical program is CYT-1853, which is designed to exploit the same novel synthetic lethality targeted by CYT-085. |
